

Trypanosoma cruzi: parasite persistence in tissues in chronic chagasic Brazilian patients

Gláucia E Barbosa Marcon¹, Dulcinéia Martins de Albuquerque¹, Angelica Martins Batista¹, Paula Durante Andrade¹, Eros A Almeida¹, Maria Elena Guariento¹, Maria AB Teixeira², Sandra C Botelho Costa^{1/+}

¹Departamento de Clínica Médica, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brasil

²Grupo de Estudo em Correlação Anátomo-Clínica, Faculdade de Medicina, Pontifícia Universidade Católica de Campinas, Campinas, SP, Brasil

Chagas disease in the chronic phase may develop into cardiac and/or digestive forms. The pathogenesis of the disease is not yet clear and studies have been carried out to elucidate the role of parasite persistence in affected organs. The aim of this study was to detect and quantify Trypanosoma cruzi in paraffin-embedded tissue samples from chronic patients using NPCR (nested polymerase chain reaction) and QPCR (quantitative polymerase chain reaction) methods. These results were correlated to anatomopathological alterations in the heart and gastrointestinal tract (GIT). Of the 23 patients studied, 18 presented the cardiac form and five presented the cardiogastrointestinal form of Chagas disease. DNA samples were randomly isolated from formalin-fixed paraffin-embedded sections of heart and GIT tissue of 23 necropsies and were analyzed through NPCR amplification. T. cruzi DNA was detected by NPCR in 48/56 (85.7%) heart and 35/42 (83.3%) GIT samples from patients with the cardiac form. For patients with the cardiogastrointestinal form, NPCR was positive in 12/14 (85.7%) heart and in 14/14 (100%) GIT samples. QPCR, with an efficiency of 97.6%, was performed in 13 samples (11 from cardiac and 2 from cardiogastrointestinal form) identified previously as positive by NPCR. The number of T. cruzi copies was compared to heart weight and no statistical significance was observed. Additionally, we compared the number of copies in different tissues (both heart and GIT) in six samples from the cardiac form and two samples from the cardiogastrointestinal form. The parasite load observed was proportionally higher in heart tissues from patients with the cardiac form. These results show that the presence of the parasite in tissues is essential to Chagas disease pathogenesis.

Key words: *Trypanosoma cruzi* - real-time PCR - nested PCR - Chagas disease

The chagasic infection caused by the *Trypanosoma cruzi* protozoan may have a different evolution based on the circumstance and situation. The parasite-host interaction is dynamic and results from several factors related to the trypanosome (strain, virulence and inoculation), the human host (age, gender and genetic profile) and the environment. *T. cruzi* infection affects between 12-14 million people and approximately 25% of the Latin American population is at risk of contracting Chagas disease (WHO 2002).

It is believed that there are two phases of the disease: the acute phase and the chronic phase. The acute phase is characterized by parasites found throughout the body, replicating within macrophages and a variety of other host cells, especially cardiac muscle cells. It is histopathologically characterized by inflammatory infiltration and tissue necrosis (Soares & Ribeiro dos Santos 1999). Following an acute infection, the chronic phase is characterized by a variable clinical course ranging from absence of symptoms to severe cardiac and/or gastrointestinal involvement (Macedo et al. 2002).

According to Köberle (1968), the number of parasites decreases from the acute to the chronic phase, both in the blood and in tissues. The period when no clinical symptoms or significant histopathological lesions are found is called the indeterminate form and can last up to 20 years. The typical chronic form of Chagas disease affects the heart in approximately 25% of the cases. Variable degrees of cardiac hypertrophy and dilatation are found with or without apical aneurysm. The other clinical form consists of dilatation of digestive organs, such as the oesophagus and the colon, as a consequence of neuronal destruction of the gastrointestinal tract (GIT) (Köberle et al. 1983).

The presence of *T. cruzi* close to the disease sites strengthens the hypothesis of parasite persistence in infected tissues, which is based on experimental results obtained through molecular biology techniques and decreased parasite load following specific treatments (Tarleton 2001). In 1993, Jones et al. (1993) detected *T. cruzi* DNA in the heart of autopsied patients by hybridized polymerase chain reaction (PCR), indicating that the persistence of parasite DNA is crucial to the disease pathogenesis and that the inflammatory process is associated with the presence of *T. cruzi* DNA in infected tissues (Vago et al. 1996).

Adad et al. (1991) reported the finding of chronic inflammatory processes in the oesophagus of asymptomatic chronic chagasic patients and in those presenting megaesophagus. These findings were confirmed

Financial support: FAPESP, CAPES

+ Corresponding author: costa@fcm.unicamp.br

Received 22 July 2010

Accepted 24 November 2010

by PCR, which amplified *T. cruzi* DNA both in the oesophagus of patients (Lages-Silva et al. 2001, Elias et al. 2003, Vago et al. 2003) and in infected murine cardiac tissue (Lane et al. 2003).

The PCR quantification method is based on the use of a fluorescent probe (TaqMan®) or fluorescent molecules (SYBR®green). This technique consists of real-time monitoring of the quantity of DNA being assessed as numerical values or the number of copies of DNA units. Recently, Duffy et al. (2009) used quantitative PCR (QPCR) to evaluate the parasitic load in children with Chagas disease, in patients under specific treatment and in cases of heart transplantation.

Real-time *T. cruzi* PCR quantification was described by Cummings and Tarleton in 2003. The examination of infected experimental models revealed sensitive and accurate quantification of parasites in host tissues, with kinetoplast DNA and satellite DNA target fragments, both repetitive regions and in a great number of copies in the *T. cruzi* genome. It was shown that the detected DNA is derived from the persistence of the parasite in the affected tissues and not from DNA persistence over long periods of time. Piron et al. (2007) used nested PCR (NPCR) and real-time techniques to detect and quantify *T. cruzi* in blood samples of chagasic patients, obtaining a similar positivity rate to results obtained by Marcon et al. (2002). The real-time PCR technique was also employed to detect *T. cruzi* in the amniotic fluid of mothers with Chagas disease (Virreira et al. 2006) and to subtype *T. cruzi* I and II in infected tissues by means of the difference in primer annealing temperatures. The real-time PCR strategy demonstrated that *T. cruzi* II is the causative agent of the tissue lesions of Chagas disease (Freitas et al. 2005).

Higuchi et al. (2003) emphasized a significant association between the presence of *T. cruzi* antigens in the heart and severe or moderate inflammation, which results from a close interaction between the host and the parasite, causing different clinical cardiac lesions.

The aim of this study was to detect and quantify *T. cruzi* DNA in tissues of chronic chagasic patients using NPCR and real-time PCR methods, respectively.

PATIENTS, MATERIALS AND METHODS

Patients and samples - The study was approved by the Research Ethics Committee of the Faculty of Medical Sciences, State University of Campinas. DNA samples isolated from paraffin-embedded tissue sections of 23 necropsied individuals with positive serologic and/or pathological tests for Chagas disease were analyzed through NPCR amplification. Out of 23 patients, 18 presented the cardiac form and five presented the cardiogastrointestinal form of Chagas disease. NPCR was performed in 70 heart tissue samples randomly extracted from sinus node, atrium-ventricular region and cardiac septum. We also analyzed 56 samples from GIT (esophagus, colon and large intestine) (Table I).

The tissues were collected during necropsies conducted between 1986-2005 at the Teaching Hospital of the Catholic University of Campinas, which supplied the epidemiologic and pathological data on the studied cases. In addition to the 126 samples, DNA was isolated

from 10 paraffin-embedded heart and GIT sections as negative controls because the patients presented negative epidemiology for Chagas disease. To verify the DNA quality and the absence of inhibitors, the human β -globin gene was amplified by NPCR (Saiki et al. 1985) in each sample.

For quantitative assays, only 13 positive NPCR DNA samples presented a minimum concentration of DNA to be used in real-time PCR as the standardized concentration for the reaction was 2 ng/ μ L. Out of 13 samples, 11 presented cardiac involvement (C1-C11) and two (CD1 and CD2) presented the cardiogastrointestinal form defined by serological and anatomopathological evidence.

The number of *T. cruzi* DNA copies determined by real-time PCR was used to establish a relationship with heart weight in 13 cases. We also compared the number of copies found in heart and GIT in 8/13 cases of the cardiac form (C1-C6) and cardiogastrointestinal form (CD1 and CD2). Quantification in GIT tissues of C7-C11 and CD3-CD5 was not possible due to the low DNA concentrations.

DNA extraction - For DNA extraction, the samples from paraffin-embedded blocks were sectioned by a microtome 12-15 times at a density of 5 μ m. A disposable blade was used for each block, avoiding any possible contamination. The sections were deparaffinized with heated xylol, hydrated (by means of successive 95% and 75% absolute ethanol baths and distilled water) and digested with proteinase K (20 μ g/ μ L) for 72 h at 60°C. After digestion, the DNA was isolated with the Qiagen DNeasy Tissue Kit - Uniscience according to the manufacturer's protocol with a final elution volume of 50 μ L.

NPCR - The NPCR was performed as previously described by our group (Marcon et al. 2002) with some modifications. The first reaction was performed with 2 μ L of the DNA sample, 50 mM of potassium chloride, 10 mM of Tris-HCl (pH 8.4), 2.5 mM magnesium chloride, 2.0 mM of each oligonucleotide (TCZ1 and TCZ2 - first reaction; TCZ3 and TCZ4 - second reaction) described in Table II, deoxyribonucleic mixture (1 mM) - dNTPs (dATP, dGTP, dCTP; dTTP) and 2.0 U of *Taq* DNA polymerase (Invitrogen) in a final volume of 30 μ L. For the second reaction, the MgCl₂ concentration was modified to 2.8 mM and a sample of the PCR product (0.5-1.0 μ L) was re-amplified with the TCZ3 and TCZ4 oligonucleotides, which resulted in a fragment of 149 base pairs (bp) for positive samples.

The amplification runs were performed with an automatic MJ Research thermocycler. Both reactions were preceded by initial denaturation at 94°C for 5 min and a final extension at 72°C for 7 min. In the first five steps, the annealing temperature was at 60°C and 65°C in the following 25 steps. The amplified fragment of 149 bp was separated by electrophoresis on a 2% agarose gel stained with ethidium bromide and visualized by ultraviolet transillumination.

Real-time PCR assay - To perform the absolute quantification, standard samples with known amounts of DNA were obtained through cloning of the internal NPCR fragment from the satellite DNA region of *T. cruzi* Y strain (TCZ3 and TCZ4 primers), resulting in the

TABLE I
Patients' data and nested polymerase chain reaction (NPCR) results in blocks of heart and gastrointestinal tract (GIT)

Necropsy	Serology	Clinical form	Anatomopathological evidences	Heart tested blocks/ positive NPCR	GIT tested blocks/ positive NPCR
C1	Positive	Cardiopathy	Heart = 620 g, myocarditis	2/2	1/1
C2	ND	Cardiopathy	Heart = 490 g	2/2	2/2
C3	Positive	Cardiopathy	Heart = 440 g	2/2	2/2
C4	Positive	Cardiopathy	Heart = 610 g, rosary bead, epycarditis	2/2	2/2
C5	Positive	Cardiopathy	Heart = 990 g, apical aneurysm, amastigotes nest	6/6	2/2
C6	Positive	Cardiopathy	Heart = 390 g, dilated cardiomyopathy	2/2	2/2
C7	Positive	Cardiopathy	Heart = 640 g	6/6	3/1
C8	Positive	Cardiopathy	Heart = 450 g, myocarditis	2/2	2/2
C9	Positive	Cardiopathy	Heart = 420 g, rosary bead, epycarditis	2/2	2/2
C10	Positive	Cardiopathy	Heart = 340 g, apical aneurysm	7/4	3/3
C11	Negative	Cardiopathy	Heart = 375 g, apical aneurysm	4/2	3/1
C12	Negative	Cardiopathy	Heart = 350 g, apical aneurysm, myocarditis	2/2	2/2
C13	Negative	Cardiopathy	Heart = 400 g, amastigotes nest	1/1	2/2
C14	Positive	Cardiopathy	Heart = 470 g, apical aneurysm	2/1	2/1
C15	Positive	Cardiopathy	Heart = 670 g, apical aneurysm, ganglionitis	1/1	3/2
C16	Positive	Cardiopathy	Heart = 540 g, apical aneurysm	9/7	5/4
C17	Positive	Cardiopathy	Heart = 580 g, dilated cardiomyopathy	2/2	2/2
C18	Positive	Cardiopathy	Heart = 565 g, apical aneurysm, dilated cardiomyopathy	2/2	2/2
CD1	Positive	Cardiodigestive	Heart = 600 g, amastigotes nest, megacolon, megaesophagus	3/3	2/2
CD2	Positive	Cardiodigestive	Heart = 560 g, apical aneurysm, ganglionitis (esophagus/colon)	2/1	2/2
CD3	Positive	Cardiodigestive	Heart = 400 g, megaesophagus	3/2	3/3
CD4	Positive	Cardiodigestive	Cardiopathy, megaesophagus	2/2	2/2
CD5	ND	Cardiodigestive	Heart = 540 g, megacolon, miocarditis	2/2	5/5

ND: not described.

six point standard curve on a logarithmic scale (Fig. 1B). For real-time PCR, we used the Sybr Green Kit, which has a fluorescent probe that intercalates into the DNA molecule and emits a light signal in each cycle.

With the optimum concentration (150 nM) of the TCZ3 and TCZ4 primers and the dilutions of the cloned product, the Ct (Cycle Threshold) vs. sample quantity standard curve was obtained. Amplification efficiency was obtained with the $E = 10^{(-1/slope)}$ formula, where *slope* corresponds to the straight-line inclination coefficient (Pfaffl 2001) given by the Gene Amp[®] SDS (Applied Biosystems) program.

Real-time PCR was performed in 25- μ L reactions, with 12.5 μ L of the *Sybr Green Mix*, 6.25 μ L of the TCZ1 and TCZ2 (150 nM) primers and 6.25 μ L of the DNA sample mix (2ng/ μ L). The samples were amplified in a thermocycler ABI Prism 7500 (Applied Biosystems) with the following PCR conditions: first step (2 min at 50°C), second step (denaturation for 10 min at 95°C) and 40 runs (15 s at 95°C and 1 min at 60°C). As an internal reaction control, the human β -actin gene was amplified

in the same amplification cycle for all samples. In each amplification step, a non-template control was subjected to the reaction to ensure that there was no contamination. The results were analyzed with the Gene Amp 7500 Sequence Detector System[®] Software (Applied Biosystems) showing fluorescence vs. number of cycles.

TABLE II

Primers for *Trypanosoma cruzi* nested polymerase chain reaction and real-time polymerase chain reaction

Primers ^a	Sequences (5'-3')
TCZ1 (forward)	CGAGCTCTTGCCACACGGGTGCT
TCZ2 (reverse)	CCTCCAAGCAGCGGATAGTTCAGG
TCZ3 (forward)	TGCTGCASTCGGCTGATCGTTTTTCGA
TCZ4 (reverse)	CARGSTTGTTGGTGTCCAGTGTGTGA

a: sequences described by Moser et al. (1989) and Ochs et al. (1996) (GenBank accession AY520036).

Statistical analysis - In the 13 cases when real-time PCR determined the parasitic load in heart tissues, we compared the number of *T. cruzi* DNA copies and heart weight of each patient using the Spearman Correlation Coefficient. This coefficient varies from -1-1; the values that are close to extremes indicate negative or positive correlation, respectively, and the values close to zero do not indicate correlation (Conover 1980). The software used was SAS System for Windows (Statistical Analysis System, version 9.1.3 Service Pack 3, SAS Institute Inc, 2002-2003, Cary, NC, USA).




Fig. 1A: quantitative real-time polymerase chain reaction (PCR) of *Trypanosoma cruzi* DNA in tissues, demonstrating the intercept (Ct) and the DNA samples; B: dynamic range of the *T. cruzi* satellite DNA based quantitative PCR. Results are expressed in logCO (log of number of copies per 2 ng/μL DNA).

RESULTS

We considered as positive samples those that presented the 149-bp amplification product (Fig. 2) obtained from NPCR of the satellite DNA region of *T. cruzi*. From the 18 patients with the cardiac form, a total of 98 samples (56 from heart tissue and 42 from GIT) were randomly analyzed and 83/98 (84.6%) were positive (48 and 35 from heart and GIT, respectively). Considering the five cases of the cardiogastrointestinal form, 26/28 (92.8%) samples were positive. In such cases, NPCR was positive for 12/14 (85.7%) of heart tissue samples and 14/14 (100%) of GIT samples as shown in Table III. There was no *T. cruzi* DNA amplification in any of the negative control samples, showing the specificity of NPCR.

The real-time PCR quantitative method was shown to be reliable and easy to handle. The TCZ3 and TCZ4 primers were standardized at a concentration of 150 nM and 2 ng/μL of DNA were used. Reaction efficiency was 97.6%, calculated by the straight-line inclination coefficient (Pfaffl 2001) with slope = - 3.467778.

To verify the specificity of the technique when using real-time PCR, every reaction was performed in duplicate and compared to the standard curve, originated from the TCZ3-TCZ4 fragment diluted in logarithmic scale (Fig. 1A, B). The minimum number of copies de-




Fig. 2: satellite DNA of *Trypanosoma cruzi* amplified by nested polymerase chain reaction. C+: Y strain of *T. cruzi*; C-: negative control; Lanes 1-4: DNA samples of tissues (heart and gastrointestinal tract); M: 100 bp DNA ladder; W: reagents with no DNA.

TABLE III

Results of nested polymerase chain reaction assay in DNA samples of gastrointestinal tract (GIT) and heart tissues

Clinical form	Patients (n)	Samples studied n (%)	GIT positives n (%)	Heart positives n (%)
Cardiac	18	83/98 (84.6)	35/42 (83.3)	48/56 (85.7)
Cardiogastrointestinal	5	26/28 (92.8)	14/14 (100)	12/14 (85.7)
Total	23	109/126 (86.5)	49/56 (87.5)	60/70 (85.7)
Negative controls	10	0/20 (0)	0/10 (0)	0/10 (0)

tected was 3.12 and the maximum was 1965.23 in 2 ng/ μ L of DNA. These data were analyzed by the Gene Amp 7500 Sequence Detector System[®] Software (Applied Biosystems) program. The human β -actin gene was amplified in all samples in the same reaction runs to assure the quality of tested samples.

TABLE IV

Number of copies found in cardiac and cardiodigestive forms in Chagas disease by quantitative polymerase chain reaction (QPCR)

Samples	Copies (n)	Clinical form
CD1- intestine	14.15	Cardiodigestive
CD1- sinus node	33.44	
CD2- GIT, no described	8.77	Cardiodigestive
CD2- right atrium, left ventricle	11.54	
C1- esophagus	5.74	Cardiac
C1- heart, apex	256.23	
C2- colon	29.2	Cardiac
C2- ventricle	283.31	
C3- esophagus	211.22	Cardiac
C3- left ventriculum, apex	681.69	
C4- colon	12.93	Cardiac
C4- left ventricle	395.87	
C5- large intestine	4.75	Cardiac
C5- left ventricle	1770.2	
C6- GIT, no described	35.45	Cardiac
C6- heart, no described	548.1	

results of quantification by QPCR in eight cases comparing number of copies between heart and gastrointestinal tract (GIT).

In eight samples assessed by real-time PCR, we compared the number of copies of *T. cruzi* DNA by QPCR between the heart and GIT and found that in cases with cardiopathy, the number of copies in the heart was higher (3.2-292 times). In the two patients with the cardiodigestive form the difference between the number of copies was lower (1.3 and 2.3 times) (Table IV).

DNA extracted from the 13 heart samples showed there was no statistical correlation between the heart weight and the number of copies found in this organ or with other pathological data (Fig. 3, Table V). Despite the low number of cases, these data suggest that parasitic loads in the affected tissues are not related to organ damage.

	Samples	Mean	SD	Minimum	Medium	Maximum
Heart weight (g)	13	525.38	180.31	280.00	490.00	990.00
Copies	13	717.95	770.66	3.12	395.87	1965.23




Fig. 3: statistical analysis. Comparison between heart weight and number of copies found by real-time polymerase chain reaction. SD: standard deviation.

TABLE V

Comparison between number of copies found by quantitative polymerase chain reaction and pathological data

Heart samples	Anatomopathological evidences	Copies (n)
C5 - left ventricle	Heart = 990 g, apical aneurysm, amastigotes nest	1770.2
C7 - left ventricle	Heart = 640 g	5.77
C1 - apical tissue	Heart = 620 g, myocarditis, myositis	256.23
C4 - left ventricle	Heart = 610 g, rosary-bead type epicarditis	395.87
CD1 - sinus node	Heart = 600 g, amastigotes nest, megacolon, megaesophagus	33.44
CD2 - right atrium, left ventricle	Heart = 560 g, ganglionitis (esophagus and colon), apical aneurysm	11.54
C2 - ventricle	Heart = 490 g	283.31
C8 - right atrium	Heart = 450 g, myocarditis	1524.05
C3 - left ventricle, apical tissue	Heart = 440 g	681.69
C9 - right atrium	Heart = 420 g	1965.23
C6 - no described	Heart = 390 g, dilated cardiomyopathy	548.1
C10 - no described	Heart = 340 g, apical aneurysm	1854.84
CD 3 - bundle of Hiss	Heart = 280 g, cardiomyopathy, megaesophagus	3.12

CD1, CD2: heart samples (cardiodigestive form), heart weight in decreasing order. Evaluation of number of copies in 13 heart samples and comparison with heart weight; C1-C11: heart samples (cardiac form).

DISCUSSION

Through NPCR, Ochs et al. (1996) suggested that *T. cruzi* was present in the heart tissues of children who died of acute Chagas disease. Significant positive association between parasite persistence in heart tissue and myocarditis was demonstrated by PCR in endomyocardial biopsies (Benvenuti et al. 2008). Knowledge of the exact role of the parasite in the pathogenesis of Chagas disease appears extremely important to guide therapeutic strategies (Higuchi et al. 2003).

The aim of this study was to detect and to quantify *T. cruzi* DNA in tissues of chronic chagasic patients. The DNA detection of parasites through NPCR in tissues corroborates previous findings of Cummings and Tarleton (2003), showing that *T. cruzi* is present in target organs and may lead to organ damage according to the immune response of each individual. The positive rate for heart and GIT tissues by NPCR was approximately 87%, confirming the high sensitivity of the technique, even in biological samples obtained from paraffin embedded-tissue sections where the fixation techniques lead to DNA loss and folding (Mesquita et al. 2001).

According to the literature, parasites are rarely found in tissues examined by routine staining techniques. However, the utilization of highly sensitive molecular biology tools, such as PCR, has revealed the presence of *T. cruzi* in involved tissues, but rarely in healthy organs of chronic chagasic patients (Ochs et al. 1996, Vago et al. 2000). When analysing oesophageal tissue and blood samples from chronic chagasic patients with megaesophagus by PCR and blood cultures, Lages-Silva et al. (2001) found that 98% of the samples were positive for *T. cruzi*, confirming the importance of the parasite in the host pathological process. In the same study, using PCR and peroxidase and anti-peroxidase, *T. cruzi* was detected in 76.9% of the analyzed megaesophagus tissues. In our investigation, this rate was 87.5% when GIT fragments were analyzed by NPCR (Table III), which indicates the presence of *T. cruzi* even when there was no clinical evidence of digestive commitment and only heart involvement.

Using NPCR-based detection of satellite DNA of *T. cruzi* in infected tissues of chagasic patients, the presence of the parasite may be related to the progression of chagasic cardiopathy and/or colonopathy. According to a review article by Tarleton (2003), authors that support the autoimmunity hypotheses in Chagas disease also admit that the persistence of the parasite plays an important role for the progression of the disease, as proven by detection of the parasite DNA, proteins and even of intact parasites in the infected tissues. Zhang and Tarleton (1999) demonstrated that parasite persistence in experimental models has absolute correlation with the severity of the illness. The detection of *T. cruzi* DNA in tissues by molecular techniques rescues the role of the parasite in Chagas disease, as well as the expression of its genes over the course of infection (Macedo et al. 2004).

When the number of copies obtained by real-time PCR in heart was compared with GIT samples, we observed that in cardiopathy cases, the number of molecules found

was proportionally higher in the heart (3.2-292 times), suggesting that the inflammatory process is related to the presence of *T. cruzi*. In the two cases with the cardiodigestive form, the difference between the numbers of copies found was significantly lower. Considering that the cardiodigestive form of Chagas disease is less frequent than the cardiac form in Brazil, it is difficult to obtain samples from the heart and GIT of a single patient (Vago et al. 2000). There certainly are several host immunologic factors and parasite antigens involved in the pathogenesis of the chagasic infection. Our findings add value to the importance of quantification of *T. cruzi* DNA by QPCR for the study of Chagas disease and may be compared, after further investigation, to techniques that use inflammatory markers to help understand the relationship between parasite loads and organ damage. According to Cummings and Tarleton (2003), doubts regarding the role of parasites found in tissues need further clarification. In our study, there was no significant statistical relationship between the heart weight and the number of amplified DNA molecules by QPCR (Fig. 3). Such results indicate that *T. cruzi* affects the target organ but the parasite loads are variable. However, a tendency towards an inverse correlation between the number of copies and the weight of the heart was noted, which might have had statistical significance if the number of cases had been higher.

In the current study, the greatest challenge was to standardize the DNA concentration at a 2 ng/ μ L. It is known that the isolation of genetic material from paraffin-embedded tissue sections yields low amounts of DNA, which is frequently fragmented, degraded and folded with proteins. Due to the low DNA concentration, some samples tested by NPCR were not quantified by real-time PCR. As genomic DNA was used, including human and *T. cruzi* DNA, we took special care to amplify β -actin gene in the same PCR cycle, imparting quality to the experimental protocol. However, the standardized technique requires less time and it presents a lower contamination risk than the NPCR.

Our data emphasizes that molecular biology tools, such as NPCR and real-time PCR, used to detect and to quantify DNA extracted from fixed tissues may contribute to a better comprehension of the pathogenesis of Chagas disease (Valadares et al. 2008). The difference in the number of copies found in different tissues by real-time PCR indicates that the variability in parasite load is associated with pathological alterations in target organs as well with disease progression.

ACKNOWLEDGEMENTS

To Sérgio Paulo de Magalhães, from Experimental Surgery and Medicine Center, School of Medical Science, UNICAMP, and to Cristiane de Oliveira, Luísa CB Keiralla and André FG Larrubia, for their assistance regarding the techniques performed.

REFERENCES

- Adad SJ, Andrade DCS, Lopes ER, Chapadeiro E 1991. Contribuição ao estudo da anatomia patológica do megaesôfago chagásico. *Rev Inst Med Trop Sao Paulo* 33: 443-450.

- Benvenuti LA, Roggério A, Freitas HF, Mansur AJ, Fiorelli A, Higuchi ML 2008. Chronic American trypanosomiasis: parasite persistence in endomyocardial biopsies is associated with high-grade myocarditis. *Ann Trop Med Parasitol* 102: 481-487.
- Conover WJ 1980. *Practical nonparametric statistics*, 2nd ed., John Wiley & Sons, New York, 592 pp.
- Cummings KL, Tarleton RL 2003. Rapid quantitation of *Trypanosoma cruzi* in host tissue by real-time PCR. *Mol Biochem Parasitol* 129: 53-59.
- Duffy T, Bisio M, Altchek J, Burgos JM, Diez M, Levin MJ, Favaloro RR, Freilij H, Schijman AG 2009. Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in Chagas disease patients. *PLoS Negl Trop Dis* 3: e419.
- Elias MC, Vargas NS, Zingales B, Schenkman S 2003. Organization of satellite DNA in the genome of *Trypanosoma cruzi*. *Mol Biochem Parasitol* 129: 1-9.
- Freitas JM, Lages-Silva E, Crema E, Pena SD, Macedo AM 2005. Real time PCR strategy for the identification of major lineages of *Trypanosoma cruzi* directly in chronically infected human tissues. *Int J Parasitol* 35: 411-417.
- Higuchi M de L, Benvenuti LA, Martins Reis M, Metzger M 2003. Pathophysiology of the heart in Chagas' disease: current status and new developments. *Cardiovasc Res* 60: 96-107.
- Jones EM, Colley DG, Tostes S, Lopes ER, Vnencak-Jones CL, McCurley TL 1993. Amplification of a *Trypanosoma cruzi* DNA sequence from inflammatory lesions in human chagasic cardiomyopathy. *Am J Trop Med Hyg* 48: 348-357.
- Köberle F 1968. Chagas disease and Chagas syndromes: the pathology of American trypanosomiasis. *Adv Parasitol* 6: 63-116.
- Köberle F, Alcântara FG, Ribeiro dos Santos R 1983. Patogenia da forma digestiva. In AA Raia, *Manifestações digestivas da moléstia de Chagas*, Sarvier, São Paulo, p. 25-34.
- Lages-Silva E, Crema E, Ramirez LE, Macedo AM, Pena SD, Chiari E 2001. Relationship between *Trypanosoma cruzi* and human chagasic megaesophagus: blood and tissue parasitism. *Am J Trop Med Hyg* 65: 435-441.
- Lane JE, Ribeiro-Rodrigues R, Olivares-Villagómez D, Vnencak-Jones CL, McCurley TL, Carter CE 2003. Detection of *Trypanosoma cruzi* DNA within murine cardiac tissue sections by in situ polymerase chain reaction. *Mem Inst Oswaldo Cruz* 98: 373-376.
- Macedo AM, Machado CR, Oliveira RP, Pena SDJ 2004. *Trypanosoma cruzi*: genetic structure of populations and relevance of genetic variability to the pathogenesis of Chagas disease. *Mem Inst Oswaldo Cruz* 99: 1-12.
- Macedo AM, Oliveira RP, Pena SD 2002. Chagas disease: role of parasite genetic variation in pathogenesis. *Expert Rev Mol Med* 4: 1-16.
- Marcon GE, Andrade PD, de Albuquerque DM, Wanderley J da S, de Almeida EA, Guariento ME, Costa SC 2002. Use of a nested polymerase chain reaction (N-PCR) to detect *Trypanosoma cruzi* in blood samples from chronic chagasic patients and patients with doubtful serologies. *Diagn Microbiol Infect Dis* 43: 39-43.
- Mesquita RA, Anzai EK, Oliveira RN, Nunes FD 2001. Avaliação de três métodos de extração de DNA de material parafinado para a amplificação de DNA genômico pela técnica de PCR. *Pesqui Odontol Bras* 15: 314-319.
- Moser DR, Kirchhoff LV, Donelson JE 1989. Detection of *Trypanosoma cruzi* by DNA amplification using the polymerase chain reaction. *J Clin Microbiol* 27: 1477-1482.
- Ochs DE, Hnilica VS, Moser DR, Smith JH, Kirchhoff LV 1996. Post-mortem diagnosis of autochthonous acute chagasic myocarditis by polymerase chain reaction amplification of a species-specific DNA sequence of *Trypanosoma cruzi*. *Am J Trop Med Hyg* 54: 526-529.
- Pfaffl MW 2001. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res* 29: 2002-2007.
- Piron M, Fisa R, Casamitjana N, López-Chejade P, Puig L, Vergés M, Gascón J, Gómez i Prat J, Portús M, Sauleda S 2007. Development of a real-time PCR assay for *Trypanosoma cruzi* detection in blood samples. *Acta Trop* 103: 195-200.
- Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N 1985. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. *Science* 230: 1350-1354.
- Soares MBP, Ribeiro dos Santos R 1999. Immunopathology of cardiomyopathy in the experimental Chagas disease. *Mem Inst Oswaldo Cruz* 94 (Suppl. I): 257-262.
- Tarleton RL 2001. Parasite persistence in the aetiology of Chagas disease. *Int J Parasitol* 31: 550-554.
- Tarleton RL 2003. Chagas disease: a role for autoimmunity? *Trends Parasitol* 19: 447-451.
- Vago AR, Andrade LO, Leite AA, d'Ávila Reis D, Macedo AM, Adad SJ, Tostes S Jr, Moreira MC, Filho GB, Pena SD 2000. Genetic characterization of *Trypanosoma cruzi* directly from tissues of patients with chronic Chagas disease: differential distribution of genetic types into diverse organs. *Am J Pathol* 156: 1805-1809.
- Vago AR, Macedo AM, Adad SJ, Reis DD, Corrêa-Oliveira R 1996. PCR detection of *Trypanosoma cruzi* DNA in oesophageal tissues of patients with chronic digestive Chagas disease. *Lancet* 348: 891-892.
- Vago AR, Silva DM, Adad SJ, Correa-Oliveira R, d'Ávila Reis D 2003. Chronic Chagas disease: presence of parasite DNA in the oesophagus of patients without megaesophagus. *Trans R Soc Trop Med Hyg* 97: 308-309.
- Valadares HM, Pimenta JR, de Freitas JM, Duffy T, Bartholomeu DC, Oliveira R de P, Chiari E, Moreira M da C, Filho GB, Schijman AG, Franco GR, Machado CR, Pena SD, Macedo AM 2008. Genetic profiling of *Trypanosoma cruzi* directly in infected tissues using nested PCR of polymorphic microsatellites. *Int J Parasitol* 38: 839-850.
- Virreira M, Martinez S, Alonso-Vega C, Torrico F, Solano M, Torrico MC, Parrado R, Truyens C, Carlier Y, Svoboda M 2006. Amniotic fluid is not useful for diagnosis of congenital *Trypanosoma cruzi* infection. *Am J Trop Med Hyg* 75: 1082-1084.
- WHO - World Health Organization 2002. WHO's Certified (database on the Internet). Control of Chagas disease (cited 2010 Jun 20). Available from: http://whqlibdoc.who.int/trs/WHO_TRS_905.pdf.
- Zhang L, Tarleton RL 1999. Parasite persistence correlates with disease severity and localization in chronic Chagas disease. *J Infect Dis* 180: 480-486.